Treasury bills have a compound return of 3.7%.
FORBES: Breaking Even Is Still Losing Money In Stocks And Bonds
Although the growth of IT jobs in the United States is slow, the growth picture is better outside the U.S. The overall number of IT positions in end-user organizations globally will grow at a 4.3% compound annual growth rate between 2011 and 2015 and reach 29.3 million in 2015, according to IDC.
FORBES: Almost 1.7 Million Cloud-Related Jobs Went Unfilled in 2012: Estimate
The reverse compound, -3%, doesn't go down 15%, but goes down say, 13% or 14%.
Now, an 8-acre family compound and the adjoining 3-acre garden are all that remain.
With such maneuvers this fund has managed a -8.3% compound annual return over the past five years, putting it in the bottom 4% of all stock funds.
FORBES: The fortunes of an aggressive growth fund in a bear market.
Since he started Pabrai Investment Funds in 1999, he has delivered a 35.3% compound annual return (after fees), to the 14.2% a year you would have made owning Berkshire shares.
For the past ten years, sales have increased at a compound annual rate of 18.3%, earnings per share at 57.2%, and dividends at 16.7%.
FORBES: Head To Canada For Bargains In Fertilizer And Energy
Assuming this figure accounts for all 1997 sequencing sales, this suggests that that the compound annual growth for sequencing has been a miserly 3.5%.
FORBES: A Reality Check On Forbes' Outrageous Prediction Of A $100 Billion DNA Industry
Though it slightly underperforms its domestic peer group in return on assets and return on equity, Popular's earnings per share are growing faster (15.3% vs. 12.7% compound annual growth over the last five years).
So when you compound that, investors have cost themselves 30%--3% a year up and 3% a year down comes out to 30%.
Also, in the one 5% plus inflation surge that was in this data set, the CRB index produced a nominal compound return of 1.58% and a real return of minus 3.32%.
The companies decided to end the program for developing the compound, called Dimebon, after it failed to meet two primary endpoints in a phase 3 trial studying its use with the existing treatment Aricept in patients with mild-to-moderate Alzheimer's.
WSJ: Medivation, Pfizer Alzheimer's Drug Fails to Meet Study Goals
应用推荐